Research progress in reversing multidrug resistance in colorectal cancer

Abstract

Wang Xi, Wu Chuanqing. Research progress in reversing multidrug resistance in colorectal cancer[J]. Journal of International Oncology, 2023, 50(1): 42-46.

References27

[1]	Zheng R, Zhang S, Zeng H, et al. Cancer incidence and mortality in China, 2016[J]. J Natl Cancer Cent, 2022, 2(1): 1-9. DOI: 10.1016/j.jncc.2022.02.002. doi:10.1016/j.jncc.2022.02.002
[2]	中华人民共和国国家卫生健康委员会. 中国结直肠癌诊疗规范(2020年版)[J]. 中华外科杂志, 2020, 58(8): 561-585. DOI: 10.3760/cma.j.cn112139-20200518-00390. doi:10.3760/cma.j.cn112139-20200518-00390
[3]	Siegel RL, Miller KD, Fuchs HE, et al. Cancer statistics, 2022[J]. CA Cancer J Clin, 2022, 72(1): 7-33. DOI: 10.3322/caac.21708. doi:10.3322/caac.21708
[4]	Bukowski K, Kciuk M, Kontek R. Mechanisms of multidrug resistance in cancer chemotherapy[J]. Int J Mol Sci, 2020, 21(9): 3233. DOI: 10.3390/ijms21093233. doi:10.3390/ijms21093233
[5]	Wang YJ, Zhang YK, Zhang GN, et al. Regorafenib overcomes chemotherapeutic multidrug resistance mediated by ABCB1 transporter in colorectal cancer: in vitro and in vivo study[J]. Cancer Lett, 2017, 396: 145-154. DOI: 10.1016/j.canlet.2017.03.011. doi:10.1016/j.canlet.2017.03.011
[6]	Grothey A, Van Cutsem E, Sobrero A, et al. Regorafenib monotherapy for previously treated metastatic colorectal cancer (CORRECT): an international, multicentre, randomised, placebo-controlled, phase 3 trial[J]. Lancet, 2013, 381(9863): 303-312. DOI: 10.1016/S0140-6736(12)61900-X. doi:10.1016/S0140-6736(12)61900-Xpmid:23177514
[7]	中华人民共和国国家卫生健康委员会医政医管局, 中华医学会肿瘤学分会. 中国结直肠癌诊疗规范(2020年版)[J]. 中国实用外科杂志, 2020, 40(6): 601-625. DOI: 10.19538/j.cjps.issn1005-2208.2020.06.01. doi:10.19538/j.cjps.issn1005-2208.2020.06.01
[8]	Schultheis B, Folprecht G, Kuhlmann J, et al. Regorafenib in combination with FOLFOX or FOLFIRI as first- or second-line treatment of colorectal cancer: results of a multicenter, phase Ⅰb study[J]. Ann Oncol, 2013, 24(6): 1560-1567. DOI: 10.1093/annonc/mdt056. doi:10.1093/annonc/mdt056pmid:23493136
[9]	Chen Y, Lu Y, Hu D, et al. Cabazitaxel-loaded MPEG-PCL copolymeric nanoparticles for enhanced colorectal cancer therapy[J]. Appl Mater Today, 2021, 25: 101210. DOI: 10.1016/j.apmt.2021.101210. doi:10.1016/j.apmt.2021.101210
[10]	Jiang Y, Guo Z, Fang J, et al. A multi-functionalized nanocomposite constructed by gold nanorod core with triple-layer coating to combat multidrug resistant colorectal cancer[J]. Mater Sci Eng C Mater Biol Appl, 2020, 107: 110224. DOI: 10.1016/j.msec.2019.110224. doi:10.1016/j.msec.2019.110224
[11]	Wang Z, Sun X, Feng Y, et al. Dihydromyricetin reverses MRP2-induced multidrug resistance by preventing NF-κB-Nrf2 signaling in colorectal cancer cell[J]. Phytomedicine, 2021, 82: 153414. DOI: 10.1016/j.phymed.2020.153414. doi:10.1016/j.phymed.2020.153414
[12]	Chen M, Liang X, Gao C, et al. Ultrasound triggered conversion of porphyrin/camptothecin-fluoroxyuridine triad microbubbles into nanoparticles overcomes multidrug resistance in colorectal cancer[J]. ACS Nano, 2018, 12(7): 7312-7326. DOI: 10.1021/acsnano.8b03674. doi:10.1021/acsnano.8b03674pmid:29901986
[13]	Carvalho RF, do Canto LM, Cury SS, et al. Drug repositioning based on the reversal of gene expression signatures identifies TOP2A as a therapeutic target for rectal cancer[J]. Cancers (Basel), 2021, 13(21): 5492. DOI: 10.3390/cancers13215492. doi:10.3390/cancers13215492
[14]	Podolski-Renić A, Banković J, Dinić J, et al. DTA0100, dual topoisomerase Ⅱ and microtubule inhibitor, evades paclitaxel resistance in P-glycoprotein overexpressing cancer cells[J]. Eur J Pharm Sci, 2017, 105: 159-168. DOI: 10.1016/j.ejps.2017.05.011. doi:S0928-0987(17)30239-7pmid:28502672
[15]	Marzi L, Sun Y, Huang SN, et al. The indenoisoquinoline LMP517: a novel antitumor agent targeting both TOP1 and TOP2[J]. Mol Cancer Ther, 2020, 19(8): 1589-1597. DOI: 10.1158/1535-7163.MCT-19-1064. doi:10.1158/1535-7163.MCT-19-1064pmid:32430490
[16]	Hientz K, Mohr A, Bhakta-Guha D, et al. The role of p53 in cancer drug resistance and targeted chemotherapy[J]. Oncotarget, 2017, 8(5): 8921-8946. DOI: 10.18632/oncotarget.13475. doi:10.18632/oncotarget.13475pmid:27888811
[17]	Ma J, Li L, Yue K, et al. Bromocoumarinplatin, targeting simultaneously mitochondria and nuclei with p53 apoptosis pathway to overcome cisplatin resistance[J]. Bioorg Chem, 2020, 99: 103768. DOI: 10.1016/j.bioorg.2020.103768. doi:10.1016/j.bioorg.2020.103768
[18]	Zhou X, Zijlstra SN, Soto-Gamez A, et al. Artemisinin derivatives stimulate DR5-specific TRAIL-induced apoptosis by regulating wildtype P53[J]. Cancers (Basel), 2020, 12(9): 2514. DOI: 10.3390/cancers12092514. doi:10.3390/cancers12092514
[19]	Wang Z, Zhan Y, Xu J, et al. β-sitosterol reverses multidrug resistance via BCRP suppression by inhibiting the p53-MDM2 interaction in colorectal cancer[J]. J Agric Food Chem, 2020, 68(12): 3850-3858. DOI: 10.1021/acs.jafc.0c00107. doi:10.1021/acs.jafc.0c00107
[20]	Wu T, Wang G, Chen W, et al. Co-inhibition of BET proteins and NF-κB as a potential therapy for colorectal cancer through synergistic inhibiting MYC and FOXM1 expressions[J]. Cell Death Dis, 2018, 9(3): 315. DOI: 10.1038/s41419-018-0354-y. doi:10.1038/s41419-018-0354-ypmid:29472532
[21]	Mosca L, Pagano M, Borzacchiello L, et al. S-Adenosylmethionine increases the sensitivity of human colorectal cancer cells to 5-fluorouracil by inhibiting P-glycoprotein expression and NF-κB activation[J]. Int J Mol Sci, 2021, 22(17): 9286. DOI: 10.3390/ijms22179286. doi:10.3390/ijms22179286
[22]	Yun UJ, Lee IH, Lee JS, et al. Ginsenoside Rp1, a ginsenoside derivative, augments anti-cancer effects of actinomycin D via downregulation of an AKT-SIRT1 pathway[J]. Cancers (Basel), 2020, 12(3): 605. DOI: 10.3390/cancers12030605. doi:10.3390/cancers12030605
[23]	Hu Y, Zhang K, Zhu X, et al. Synergistic inhibition of drug-resistant colon cancer growth with PI3K/mTOR dual inhibitor BEZ235 and nano-emulsioned paclitaxel via reducing multidrug resistance and promoting apoptosis[J]. Int J Nanomedicine, 2021, 16: 2173-2186. DOI: 10.2147/IJN.S290731. doi:10.2147/IJN.S290731
[24]	Toyoda M, Watanabe K, Amagasaki T, et al. A phase Ⅰ study of single-agent BEZ235 special delivery system sachet in Japanese patients with advanced solid tumors[J]. Cancer Chemother Pharmacol, 2019, 83(2): 289-299. DOI: 10.1007/s00280-018-3725-2. doi:10.1007/s00280-018-3725-2
[25]	ClinicalTrials. gov. Azacitidine and CAPOX in metastatic colorectal cancer[EB/OL]. [2020-04-15] [2022-07-26]. https://clinicaltrials.gov/ct2/show/results/NCT01193517.
[26]	ClinicalTrials. gov. Study comparing veliparib plus FOLFIRI versus placebo plus FOLFIRI with or without bevacizumab in previously untreated metastatic colorectal cancer[EB/OL]. [2018-11-20] [2022-07-26]. https://clinicaltrials.gov/ct2/show/results/NCT02305758.
[27]	Huang TH, Wu SY, Huang YJ, et al. The identification and validation of Trichosstatin A as a potential inhibitor of colon tumorige-nesis and colon cancer stem-like cells[J]. Am J Cancer Res, 2017, 7(5): 1227-1237.

Research progress in reversing multidrug resistance in colorectal cancer

RichHTML

PDF

Knowledge

Abstract

Cite this article

share this article

References27

Related Articles15

Recommended Articles

Metrics

Comments

[1]	Zhang Rui, Chu Yanliu.Research progress of colorectal cancer risk assessment models based on FIT and gut microbiota[J]. Journal of International Oncology, 2024, 51(6): 370-375.
[2]	Gao Fan, Wang Ping, Du Chao, Chu Yanliu.Research progress on intestinal flora and non-surgical treatment of the colorectal cancer[J]. Journal of International Oncology, 2024, 51(6): 376-381.
[3]	Wang Junyi, Hong Kaibin, Ji Rongjia, Chen Dachao.Effect of cancer nodules on liver metastases after radical resection of colorectal cancer[J]. Journal of International Oncology, 2024, 51(5): 280-285.
[4]	Yang Zhi, Lu Yiqiao, Gu Huayan, Ding Jialing, Guo Guilong.Research progress of tumor microenvironment mediated drug resistance in targeted therapy of breast cancer[J]. Journal of International Oncology, 2024, 51(4): 235-238.
[5]	Gong Yan, Chen Honglei.Research progress on the mechanism of microRNA regulation of cisplatin resistance in ovarian cancer[J]. Journal of International Oncology, 2024, 51(3): 186-190.
[6]	Sun Guobao, Yang Qian, Zhuang Qingchun, Gao Binbin, Sun Xiaogang, Song Wei, Sha Dan.Research progress on the histopathological growth patterns of colorectal liver metastasis[J]. Journal of International Oncology, 2024, 51(2): 114-118.
[7]	Liu Debao, Sun Ziwen, Lu Shoutang, Xu Haidong.Expression and clinical significance of ASB6 in colorectal cancer tissues[J]. Journal of International Oncology, 2023, 50(8): 470-474.
[8]	An Rong, Liu Meihua, Wang Peichen, Wang Xiaohui.Research progress of Nrf2 in ovarian cancer[J]. Journal of International Oncology, 2023, 50(8): 493-497.
[9]	Chen Zhuo, Tao Jun, Chen Lin, Ke Jing.Value of detection of peripheral blood miR-194 combined with fecal miR-143 in the clinical screening of colorectal cancer[J]. Journal of International Oncology, 2023, 50(5): 268-273.
[10]	Huang Zhen, Zhang Caiyutian, Ke Shaobo, Shi Wei, Zhao Wensi, Chen Yongshun.Construction of postoperative prognosis model for patients with colorectal cancer[J]. Journal of International Oncology, 2023, 50(3): 157-163.
[11]	Xu Liangfu, Li Yuanfei.Research progress on tumor microenvironment and immune combination therapy of MSS colorectal cancer[J]. Journal of International Oncology, 2023, 50(3): 186-190.
[12]	Liu Yujie, Zhao Zhiqiang, Wang Zicheng.Levels and diagnostic value of TOP2A and ERBB2 in peripheral blood mononuclear cells of patients with early colorectal cancer[J]. Journal of International Oncology, 2023, 50(12): 717-722.
[13]	Tao Hong, Yin Hong, Luo Hong, Tao Jiayu.Potential strategies for targeting tumor-associated macrophages to enhance the efficacy of immune checkpoint inhibitors for colorectal cancer[J]. Journal of International Oncology, 2023, 50(11): 683-687.
[14]	Liu Xiaojie, Huang Junxing.Research progress of NADPH oxidase 2 in malignant tumors[J]. Journal of International Oncology, 2023, 50(10): 618-621.
[15]	Ma Xiaoping, Chang Junli, Sun Xingyuan, Yang Yanping.Study progression on mechanism of long non-coding RNAs regulating drug resistance in osteosarcoma[J]. Journal of International Oncology, 2023, 50(1): 51-54.